Literature DB >> 4622666

Metabolic studies of 3 H-orphenadrine citrate in the rat, dog and rhesus monkey.

T Ellison.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 4622666

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN： 0003-9780


× No keyword cloud information.
  4 in total

Review 1.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 2.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Anticholinergic antiparkinson drug orphenadrine inhibits HERG channels: block attenuation by mutations of the pore residues Y652 or F656.

Authors:  Eberhard P Scholz; Franziska M Konrad; Daniel L Weiss; Edgar Zitron; Claudia Kiesecker; Ramona Bloehs; Martin Kulzer; Dierk Thomas; Sven Kathöfer; Alexander Bauer; Martin H Maurer; Gunnar Seemann; Hugo A Katus; Christoph A Karle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-27       Impact factor: 3.000

4.  Difference between single and multiple dose pharmacokinetics of orphenadrine hydrochloride in man.

Authors:  J J Labout; C t Thijssen; G G Keijser; W Hespe
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.